Navigation Links
Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
Date:2/26/2008

ourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. CardioDynamics Provides 2007 Shareholder Meeting Update
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 XenoTech announces an exclusive ... metabolite production from bioactive small molecules. Based ... technology enables convenient and timely assessment of critical ... Vice President of Commercial Operations, Christian Darabant, “the ... risk can be measured directly by comparison with ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... , August 18, 2014 ... Systems Market, By Application (Municipal Wastewater Treatment and ... Sheet and Multi Tubular), By Configuration (Internal/Submerged and ... published by MarketsandMarkets, The market for membrane bioreactor ... 2019, growing at a CAGR of 15.28% between ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company ... to regress atherosclerotic plaque, announced the recent presentation ... Division of Cardiology at the David Geffen School ... Heart Association (AHA) Scientific Sessions in Orlando, Florida.  ...
... 2011  If algae is to be the solution for America,s ... make that a reality. Applications are now available for continuing ... retrain workers as general science technicians in the rapidly expanding ... Approximately 55 students will begin classes in ...
... 22, 2011 Sequenom, Inc. (NASDAQ: SQNM ), ... announced the Company,s participation at the 23rd Annual Piper Jaffray ... November 29-30, 2011. Ronald M. Lindsay, Ph.D., ... Maier, CFO, will present on Tuesday, November 29, 2011 beginning ...
Cached Biology Technology:AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 2Free Job Training: 55 Grants Available to Retrain Workers for Biofuels Industry 3Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference 2
(Date:8/19/2014)... crocodiles colonised the seas during warm phases and became ... study which establishes a link between marine crocodilian diversity ... of more than 140 million years. , The ... de Lyon, France and formerly from the University of ... Communications ., Today, crocodiles are ,cold-blooded, animals that mainly ...
(Date:8/19/2014)... The University of Texas Health Science Center at San ... (UTSA) today announced the awarding of more than $750,000 ... (SALSI) Innovation Challenge. , Launched in 2003, SALSI is ... and an academic health science center join forces for ... funds collaborative studies, with a focus on public health ...
(Date:8/19/2014)... has been awarded a nearly $40,000 grant from the ... office of the National Park Service (NPS) and U.S. ... one-year study of the energy efficiency and cost effectiveness ... humid climates. , Radiant barriers are reflective thermal insulations ... back, thereby reducing the amount of heat emitted in ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2San Antonio Life Sciences Institute awards $750,000 to innovators 2San Antonio Life Sciences Institute awards $750,000 to innovators 3UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... vegetative cover, strong winds, dry, non-cohesive sandy soils, ... resources of Abu Dhabi Emirate in the United ... stresses, including wind erosion, salinization, waterlogging, landfilling, and ... Dhabi Emirate, land degradation is a matter of ...
... have found a way to save time, money and ... shed light on the biological processes associated with all ... genetics, and postdoctoral associate Matthew C. Hale have provided ... necessary with recent advances in DNA sequencing technology. Instead, ...
... Pfizer Inc., a major biopharmaceutical company, and the Wisconsin ... licensing organization for the University of Wisconsin-Madison, announced May ... embryonic stem (hES) cell patents for the development of ... the rights to work with hES cells for drug ...
Cached Biology News:Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2Random picks better than complicated process in gene identification 2WARF signs license agreement with Pfizer for human embryonic stem cells 2
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
...
Biology Products: